Piramal Pharma
204.73
+1.35(+0.66%)
Market Cap₹27,034.20 Cr
PE Ratio296.52
IndustryHealthcare
Company Performance:
1D+0.66%
1M-0.46%
6M-20.72%
1Y+29.32%
5Y+10.34%
View Company Insightsright
Latest news about Piramal Pharma
Piramal Pharma's Aurora Facility Passes USFDA Inspection with Flying Colors Jun 02, 2025
Piramal Pharma Limited's Aurora facility has successfully passed a USFDA inspection with zero Form 483 observations, receiving a No Action Indicated (NAI) status. This outcome demonstrates the facility's adherence to stringent quality and regulatory standards, potentially boosting market confidence and ensuring operational continuity. The flawless inspection result underscores Piramal Pharma's commitment to maintaining high-quality manufacturing practices in the pharmaceutical industry.
Piramal Pharma's Quarterly Results In Line with Expectations; Goldman Sachs Remains Bullish on Profit Growth Potential May 16, 2025
Piramal Pharma Reports Robust Q4 FY2023 Results with 48% Profit Surge May 14, 2025
Piramal Pharma Invests $90 Million in US Facilities Expansion Amid Growing Demand May 13, 2025
Piramal Pharma Commits $90 Million for US Facility Expansions May 12, 2025
More news about Piramal Pharma
02Apr 25
Piramal Pharma Expands Anesthesia Portfolio with Sevoflurane Production in Telangana
Piramal Pharma Limited (PPL) has begun commercial production of Sevoflurane, an inhalational anesthetic, at its Digwal, Telangana facility. This expansion complements their existing production in Bethlehem, Pennsylvania, USA. The move aims to tap into Rest of World (ROW) markets beyond the USA, enhancing PPL's global competitiveness in the anesthesia market. The dual manufacturing locations are expected to provide increased supply chain flexibility and wider market access.
21Mar 25
Piramal Critical Care's Neoatricon® Receives MHRA Approval for Pediatric Hypotension Treatment
Piramal Pharma Limited's Critical Care division announced MHRA approval for Neoatricon®, a novel pediatric formulation of Dopamine Hydrochloride for treating hypotension in neonates, infants, and children. Developed by BrePco Biopharma Limited, Neoatricon® is the first approved pediatric-strength solution for Dopamine Hydrochloride infusion. Piramal Critical Care has secured commercialization rights for the EU, UK, and Norway. The product offers age-appropriate formulations, improved safety, and enhanced efficiency in critical care settings.
20Mar 25
Piramal Critical Care's Neoatricon® Secures MHRA Approval for Pediatric Hypotension Treatment
Piramal Pharma Limited's Critical Care division has received MHRA approval for Neoatricon®, a pediatric formulation for treating hypotension in neonates, infants, and children. Developed with BrePco Biopharma, it's the first pediatric-strength Dopamine Hydrochloride solution for infusion. Available in two concentrations, Neoatricon® offers precise dosing, reduced preparation time, and minimizes risks associated with adult formulations. Piramal has secured commercialization rights in the EU, UK, and Norway, marking its expansion into a new therapeutic area.
18Feb 25
Piramal Pharma's Turbhe Facility Receives FDA Form-483 with Six Observations
Piramal Pharma Limited's Turbhe facility underwent a GMP inspection by the US FDA from February 11-17, 2025, resulting in a Form-483 with six observations. The company stated these observations are primarily for procedure improvements and not related to data integrity issues. Piramal Pharma is preparing a detailed response within the stipulated timelines. The company also announced changes to its Registrar and Share Transfer Agent, now MUFG Intime India Private Limited, and scheduled investor meetings in Hong Kong.
Piramal Pharma
204.73
+1.35
(+0.66%)
1 Year Returns:+29.32%
Industry Peers
Sun Pharmaceutical
1,667.20
(-0.51%)
Divis Laboratories
6,856.50
(+0.69%)
Cipla
1,515.70
(+0.65%)
Torrent Pharmaceuticals
3,416.70
(+0.25%)
Dr Reddys Laboratories
1,276.80
(-0.51%)
Zydus Life Science
1,002.50
(+1.27%)
Mankind Pharma
2,287.00
(-1.41%)
Lupin
1,960.90
(+1.18%)
Abbott
34,665.00
(-2.82%)
Aurobindo Pharma
1,132.50
(-0.20%)